Risk Of Thrombosis In Elderly Immune Primary Trombocytopenic Patients Treated with Thrombopoietin Receptors Agonists

J Thromb Thrombolysis. 2020 Nov;50(4):903-907. doi: 10.1007/s11239-020-02083-x.

Authors

Roberto Castelli¹, Antonio Gidaro², Giorgio Lambertenghi Deliliers³

Affiliations

¹ Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Luigi Sacco Hospital, Milan, Italy. [email protected].
² Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Luigi Sacco Hospital, Milan, Italy.
³ Fondazione Mattarelli, Milan, Italy.

PMID: 32347510
DOI: 10.1007/s11239-020-02083-x

No abstract available

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Female
Humans
Male
Middle Aged
Purpura, Thrombocytopenic, Idiopathic / drug therapy*
Receptors, Thrombopoietin / agonists*
Risk Factors
Thrombosis / chemically induced*

Substances

Receptors, Thrombopoietin